{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:48:23Z","timestamp":1791931703996,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81125009"],"award-info":[{"award-number":["81125009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The research foundation for distinguished scholar of Zhejiang University","award":["188020-193810101\/089"],"award-info":[{"award-number":["188020-193810101\/089"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spinocerebellar ataxia type 3 (SCA3) is the most common subtype of autosomal dominantly inherited spinocerebellar ataxias (SCAs). No validated blood biomarker is available to assess either disease progression or therapeutic response. Neurofilament light chain (NfL) was recently proposed as a serum biomarker for many neurodegenerative disorders. The present study investigated whether NfL was a promising serum biomarker for SCA3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seventeen SCA3 patients and 9 controls were enrolled in cohort A, and 116 SCA3 individuals (preclinical and patients) and 91 controls were recruited as cohort B. We assessed whether serum NfL correlated with cerebrospinal fluid (CSF) NfL in cohort A and correlations between serum NfL levels and clinical features and brain volumes were determined in cohort B. The single-molecule array method was used to measure serum NfL levels. Disease severity was determined using the scale for the assessment and rating of ataxia (SARA) and the international cooperative ataxia rating scale (ICARS). Cerebellar and brainstem volumes were assessed using MRI neuroimaging measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum\/CSF NfL levels in cohort A were elevated in SCA3 patients, and serum and CSF NfL exhibited a significant positive correlation (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.9179,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Levels of serum NfL in cohort B were significantly higher in preclinical SCA3 (15.03\u2009\u00b1\u20097.49 vs 6.88\u2009\u00b1\u20092.72\u2009pg\/ mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and manifest SCA3 subjects (37.56\u2009\u00b1\u200913.47 vs 9.07\u2009\u00b1\u20096.02\u2009pg\/ mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) compared to those in controls. Serum NfL concentrations increased from early disease stage to the next stage. Levels of serum NfL in\n                      <jats:italic>ATXN3<\/jats:italic>\n                      mutation carriers were positively associated with SARA (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.5458,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and ICARS scores (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.5522,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Significant negative associations with cerebellar volumes (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.4217,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0003) and brainstem volumes (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.4263,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0003) were observed. All changes remained significant after adjustment for age and CAG repeat.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Levels of serum NfL were significantly elevated in SCA3 individuals and correlated with disease severity. Serum NfL is a promising serum biomarker of disease onset and progression, and a potential candidate biomarker of treatment response in SCA3.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-019-0338-0","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T10:04:42Z","timestamp":1572861882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3"],"prefix":"10.1186","volume":"14","author":[{"given":"Quan-Fu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Juan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Ling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-572X","authenticated-orcid":false,"given":"Zhi-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"338_CR1","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaneurol.2013.1707","volume":"70","author":"P Coutinho","year":"2013","unstructured":"Coutinho P, Ruano L, Loureiro JL, Cruz VT, Barros J, Tuna A, et al. Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study. JAMA Neurol. 2013;70:746\u201355.","journal-title":"JAMA Neurol"},{"key":"338_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12311-013-0510-y","volume":"13","author":"RM de Castilhos","year":"2014","unstructured":"de Castilhos RM, Furtado GV, Gheno TC, Schaeffer P, Russo A, Barsottini O, et al. Spinocerebellar ataxias in Brazil--frequencies and modulating effects of related genes. Cerebellum. 2014;13:17\u201328.","journal-title":"Cerebellum"},{"key":"338_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2350-11-47","volume":"11","author":"SR Gan","year":"2010","unstructured":"Gan SR, Shi SS, Wu JJ, Wang N, Zhao GX, Weng ST, et al. High frequency of Machado-Joseph disease identified in southeastern Chinese kindreds with spinocerebellar ataxia. BMC Med Genet. 2010;11:47.","journal-title":"BMC Med Genet"},{"key":"338_CR4","first-page":"139","volume":"61","author":"J Sequeiros","year":"1993","unstructured":"Sequeiros J, Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. Adv Neurol. 1993;61:139\u201353.","journal-title":"Adv Neurol"},{"key":"338_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1468-1331.2009.02639.x","volume":"16","author":"SR Gan","year":"2009","unstructured":"Gan SR, Zhao K, Wu ZY, Wang N, Murong SX. Chinese patients with Machado-Joseph disease presenting with complicated hereditary spastic paraplegia. Eur J Neurol. 2009;16:953\u20136.","journal-title":"Eur J Neurol"},{"issue":"2","key":"338_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s12311-011-0316-8","volume":"11","author":"JA Saute","year":"2012","unstructured":"Saute JA, Donis KC, Serrano-Munuera C, Genis D, Ramirez LT, Mazzetti P, et al. Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials. Cerebellum. 2012;11(2):488\u2013504.","journal-title":"Cerebellum"},{"issue":"7","key":"338_CR7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/mds.26238","volume":"30","author":"M Raposo","year":"2015","unstructured":"Raposo M, Bettencourt C, Maciel P, Gao F, Ramos A, Kazachkova N, et al. Novel candidate blood-based transcriptional biomarkers of Machado-Joseph disease. Mov Disord. 2015;30(7):968\u201375.","journal-title":"Mov Disord"},{"key":"338_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fneur.2017.00485","volume":"8","author":"AM de Assis","year":"2017","unstructured":"de Assis AM, Saute J, Longoni A, Haas CB, Torrez VR, Brochier AW, et al. Peripheral oxidative stress biomarkers in spinocerebellar Ataxia type 3\/Machado-Joseph disease. Front Neurol. 2017;8:485.","journal-title":"Front Neurol"},{"key":"338_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12311-015-0719-z","volume":"15","author":"SCG Da","year":"2016","unstructured":"Da SCG, Saute JA, Haas CB, Torrez VR, Brochier AW, Souza GN, et al. Cytokines in Machado Joseph disease\/spinocerebellar Ataxia 3. Cerebellum. 2016;15:518\u201325.","journal-title":"Cerebellum"},{"key":"338_CR10","doi-asserted-by":"publisher","first-page":"413098","DOI":"10.1155\/2015\/413098","volume":"2015","author":"AM Brouillette","year":"2015","unstructured":"Brouillette AM, Oz G, Gomez CM. Cerebrospinal fluid biomarkers in spinocerebellar Ataxia: a pilot study. Dis Markers. 2015;2015:413098.","journal-title":"Dis Markers"},{"key":"338_CR11","doi-asserted-by":"publisher","first-page":"2316.e17","DOI":"10.1016\/j.neurobiolaging.2010.03.014","volume":"32","author":"S Persengiev","year":"2011","unstructured":"Persengiev S, Kondova I, Otting N, Koeppen AH, Bontrop RE. Genome-wide analysis of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar ataxia pathogenesis. Neurobiol Aging. 2011;32:2316.e17\u201327.","journal-title":"Neurobiol Aging"},{"key":"338_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1474-4422(13)70104-2","volume":"12","author":"H Jacobi","year":"2013","unstructured":"Jacobi H, Reetz K, du Montcel ST, Bauer P, Mariotti C, Nanetti L, et al. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol. 2013;12:650\u20138.","journal-title":"Lancet Neurol"},{"issue":"Pt 3","key":"338_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/brain\/aws369","volume":"136","author":"K Reetz","year":"2013","unstructured":"Reetz K, Costa AS, Mirzazade S, Lehmann A, Juzek A, Rakowicz M, et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain. 2013;136(Pt 3):905\u201317.","journal-title":"Brain"},{"key":"338_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1148\/radiol.13130531","volume":"270","author":"G Oz","year":"2014","unstructured":"Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014;270:658\u201379.","journal-title":"Radiology"},{"key":"338_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12035-008-8033-0","volume":"38","author":"R Perrot","year":"2008","unstructured":"Perrot R, Berges R, Bocquet A, Eyer J. Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol. 2008;38:27\u201365.","journal-title":"Mol Neurobiol"},{"key":"338_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos R, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol. 2017;16:601\u20139.","journal-title":"Lancet Neurol"},{"key":"338_CR17","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","volume":"89","author":"P Weston","year":"2017","unstructured":"Weston P, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology. 2017;89:2167\u201375.","journal-title":"Neurology"},{"key":"338_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","volume":"74","author":"A Gaiani","year":"2017","unstructured":"Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: Neurofilament light chain levels in definite subtypes of disease. JAMA Neurol. 2017;74:525\u201332.","journal-title":"JAMA Neurol"},{"key":"338_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857\u201370.","journal-title":"Ann Neurol"},{"key":"338_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IO, Dick KM, Brotherhood E, Gordon E, Fellows A, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87:1329\u201336.","journal-title":"Neurology"},{"key":"338_CR21","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"A Sandelius","year":"2018","unstructured":"Sandelius A, Zetterberg H, Blennow K, Adiutori R, Malaspina A, Laura M, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90:e518\u201324.","journal-title":"Neurology"},{"key":"338_CR22","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeno JC, et al. Diagnostic value of cerebrospinal fluid Neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019; Epub ahead of print."},{"key":"338_CR23","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s00415-018-8893-9","volume":"265","author":"C Wilke","year":"2018","unstructured":"Wilke C, Bender F, Hayer SN, Brockmann K, Schols L, Kuhle J, et al. Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol. 2018;265:1618\u201324.","journal-title":"J Neurol"},{"issue":"1","key":"338_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1212\/WNL.0000000000001711","volume":"85","author":"RP Maas","year":"2015","unstructured":"Maas RP, van Gaalen J, Klockgether T, van de Warrenburg BP. The preclinical stage of spinocerebellar ataxias. Neurology. 2015;85(1):96\u2013103.","journal-title":"Neurology"},{"key":"338_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12021-018-9385-x","volume":"17","author":"PA Yushkevich","year":"2019","unstructured":"Yushkevich PA, Pashchinskiy A, Oguz I, Mohan S, Schmitt JE, Stein JM, et al. User-guided segmentation of multi-modality medical imaging datasets with ITK-SNAP. Neuroinformatics. 2019;17:83\u2013102.","journal-title":"Neuroinformatics"},{"key":"338_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature10671","volume":"480","author":"P Koch","year":"2011","unstructured":"Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, Poppe D, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 2011;480:543\u20136.","journal-title":"Nature"},{"key":"338_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-3-319-71779-1_18","volume":"1049","author":"C Nobrega","year":"2018","unstructured":"Nobrega C, Simoes AT, Duarte-Neves J, Duarte S, Vasconcelos-Ferreira A, Cunha-Santos J, et al. Molecular mechanisms and cellular pathways implicated in Machado-Joseph disease pathogenesis. Adv Exp Med Biol. 2018;1049:349\u201367.","journal-title":"Adv Exp Med Biol"},{"key":"338_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ana.25297","volume":"84","author":"T Rezende","year":"2018","unstructured":"Rezende T, de Paiva J, Martinez A, Lopes-Cendes I, Pedroso JL, Barsottini O, et al. Structural signature of SCA3: from presymptomatic to late disease stages. Ann Neurol. 2018;84:401\u20138.","journal-title":"Ann Neurol"},{"key":"338_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12035-018-1069-x","volume":"56","author":"M Raposo","year":"2019","unstructured":"Raposo M, Ramos A, Santos C, Kazachkova N, Teixeira B, Bettencourt C, et al. Accumulation of mitochondrial DNA common deletion since the Preataxic stage of Machado-Joseph disease. Mol Neurobiol. 2019;56:119\u201324.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"338_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-018-0261-9","volume":"13","author":"L Toonen","year":"2018","unstructured":"Toonen L, Overzier M, Evers MM, Leon LG, van der Zeeuw S, Mei H, et al. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model. Mol Neurodegener. 2018;13(1):31.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"338_CR31","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1007\/s12035-018-1332-1","volume":"56","author":"S Esteves","year":"2019","unstructured":"Esteves S, Oliveira S, Duarte-Silva S, Cunha-Garcia D, Teixeira-Castro A, Maciel P. Preclinical evidence supporting early initiation of citalopram treatment in Machado-Joseph disease. Mol Neurobiol. 2019;56(5):3626\u201337.","journal-title":"Mol Neurobiol"},{"issue":"20","key":"338_CR32","doi-asserted-by":"publisher","first-page":"e1780","DOI":"10.1212\/WNL.0000000000005518","volume":"90","author":"P Shahim","year":"2018","unstructured":"Shahim P, Tegner Y, Marklund N, Blennow K, Zetterberg H. Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology. 2018;90(20):e1780\u20138.","journal-title":"Neurology"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-019-0338-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13024-019-0338-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-019-0338-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T19:16:28Z","timestamp":1604344588000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-019-0338-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1186\/s13024-019-0338-0","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"22 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee of Second Affiliated Hospital, Zhejiang University School of Medicine in Hangzhou, China approved this study. Each participant gave an informed written consent before enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}